Understanding the Radiobiological Mechanisms Induced by (177)Lu-DOTATATE in Comparison to External Beam Radiation Therapy.

Authors : Delbart W, Karabet J, Marin G, Penninckx S, Derrien J, Ghanem GE, Flamen P, Wimana Z
Year : 2022
Journal : Int J Mol Sci
Volume : 23

Everolimus-induced somatostatin receptor overexpression in a rectal neuroendocrine tumor patient may promote somatostatin receptor-guided radionuclide therapy (peptide receptor radiotherapy) as an additional treatment option.

Authors : Mileva M, Wimana Z, Flamen P, Karfis I
Year : 2021
Journal : World J Nucl Med
Volume : 20
Pages : 316-318

Downregulation of the FTO m⁶A RNA demethylase promotes EMT-mediated progression of epithelial tumors and sensitivity to Wnt inhibitors.

Authors : Jeschke J, Collignon E, Al Wardi C, Krayem M, Bizet M, Jia Y, Garaud S, Wimana Z, Calonne E, Hassabi B, Morandini R, Deplus R, Putmans P, Dube G, Singh NK, Koch A, Shostak K, Rizzotto L, Ross RL, Desmedt C, Bareche Y, Rothé F, Lehmann-Che J, Duterque-Coquillaud M, Leroy X, Menschaert G, Teixeira L, Guo M, Limbach PA, Close P, Chariot A, Leucci E, Ghanem G, Yuan BF, Willard-Gallo K, Sotiriou C, Marine JC, Fuks F
Year : 2021
Journal : Nat Cancer
Volume : 2
Pages : 611-628

Investigating intrinsic radiosensitivity biomarkers to peptide receptor radionuclide therapy with [¹⁷⁷Lu]Lu-DOTATATE in a panel of cancer cell lines.

Authors : Delbart W, Ghanem G, Karfis I, Flamen P, Wimana Z
Year : 2021
Journal : Nucl Med Biol
Volume : 96-97
Pages : 68-79

A Technologist’s guide, radiopharmacy: an update. Chapter 2: Theoretical Basics of Radiopharmacy, Zéna Wimana, 18-29.

Authors : Wimana Z
Year : 2019
Journal : Book
Volume : chapter 2
Pages : 18-29

Tumor Drug Penetration Measurements Could Be the Neglected Piece of the Personalized Cancer Treatment Puzzle.

Authors : Bartelink IH, Jones EF, Shahidi-Latham SK, Lee PRE, Zheng Y, Vicini P, van t Veer L, Wolf D, Iagaru A, Kroetz DL, Prideaux B, Cilliers C, Thurber GM, Wimana Z, Gebhart G
Year : 2019
Journal : Clin Pharmacol Ther
Volume : 106
Pages : 148-163

68Ga-PSMA PET/CT-based metastasis-directed radiotherapy for oligometastatic prostate cancer recurrence after radical prostatectomy.

Authors : Artigas C, Flamen P, Charlier F, Levillain H, Wimana Z, Diamand R, Albisinni S, Gil T, Velthoven Rv, Peltier A, Van Gestel D, Roumeguere T, Otte FX
Year : 2019
Journal : World J Urol
Volume : 37
Pages : 1535-1542

A dosimetry procedure for organs-at-risk in ¹⁷⁷Lu peptide receptor radionuclide therapy of patients with neuroendocrine tumours.

Authors : Marin G, Vanderlinden B, Karfis I, Guiot T, Wimana Z, Reynaert N, Vandenberghe S, Flamen P
Year : 2018
Journal : Phys Med
Volume : 56
Pages : 41-49

N-Acetylcysteine breaks resistance to trastuzumab caused by MUC4 overexpression in human HER2 positive BC-bearing nude mice monitored by 89Zr-Trastuzumab and 18F-FDG PET imaging.

Authors : Wimana Z, Gebhart G, Guiot T, Vanderlinden B, Larsimont D, Doumont G, Van Simaeys G, Goldman S, Flamen P, Ghanem G
Year : 2017
Journal : Oncotarget
Volume : 8(34)
Pages : 56185-56198

Value of the 68Ga-DOTATATE PET-CT in the diagnosis of endometriosis. A pilot study.

Authors : Fastrez M, Artigas C, Sirtaine N, Wimana Z, Caillet M, Rozenberg S, Flamen P
Year : 2017
Journal : Eur J Obstet Gynecol Reprod Biol
Volume : 212
Pages : 69-74

Accuracy and precision assessment for activity quantification in individualized dosimetry of 177Lu-DOTATATE therapy.

Authors : Marin G, Vanderlinden B, Karfis I, Guiot T, Wimana Z, Flamen P, Vandenberghe S
Year : 2017
Journal : EJNMMI Phys
Volume : 4
Pages : 7

Imaging Diagnostic and Therapeutic Targets: Human Epidermal Growth Factor Receptor 2.

Authors : Gebhart G, Flamen P, de Vries EG, Jhaveri K, Wimana Z
Year : 2016
Journal : J Nucl Med
Volume : 57 Suppl 1
Pages : 81S-8S

Paget bone disease demonstrated on 68Ga-PSMA ligand PET/CT.

Authors : Artigas C, Alexiou J, Garcia C, Wimana Z, Otte FX, Gil T, Van Velthoven R, Flamen P
Year : 2016
Journal : Eur J Nucl Med Mol Imaging
Volume : 43(1)
Pages : 195-6

Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR Trial.

Authors : Gebhart G, Lamberts LE, Wimana Z, Garcia C, Emonts P, Ameye L, Stroobants S, Huizing M, Aftimos P, Tol J, Oyen WJ, Vugts DJ, Hoekstra OS, Schröder CP, Menke-van der Houven van Oordt CW, Guiot T, Brouwers AH, Awada A, de Vries EG, Flamen P
Year : 2016
Journal : Ann Oncol
Volume : 27(4)
Pages : 619-24

Mucolytic Agents Can Enhance HER2 Receptor Accessibility for [(89)Zr]Trastuzumab, Improving HER2 Imaging in a Mucin-Overexpressing Breast Cancer Xenograft Mouse Model.

Authors : Wimana Z, Gebhart G, Guiot T, Vanderlinden B, Morandini R, Doumont G, Sherer F, Van Simaeys G, Goldman S, Ghanem G, Flamen P
Year : 2015
Journal : Mol Imaging Biol
Volume : 17(5)
Pages : 697-703